Patents by Inventor Matthias Eckhardt

Matthias Eckhardt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists
    Patent number: 11992494
    Abstract: Cyclopentathiophene carboxamides of formula (I), wherein R1, R2, R3, R4, and n are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of formula (I) can be used in methods for the treatment of diseases which can be influenced by antagonizing the activity mediated by the platelet activating factor receptor.
    Type: Grant
    Filed: December 19, 2022
    Date of Patent: May 28, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Ferenc Kontes, Christofer Siegfried Tautermann, Dieter Wiedenmayer, Marina Kristina Willwacher
  • HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS
    Publication number: 20240076286
    Abstract: Disclosed are heteroaromatic carboxamides of formula (I), wherein Y, R, and Ar are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are the use of the compounds of formula (i) for the treatment of diseases which can be influenced by the inhibition of plasma kallikrein.
    Type: Application
    Filed: September 18, 2023
    Publication date: March 7, 2024
    Inventors: Matthias ECKHARDT, Maude GIROUD, Elke LANGKOPF, Camilla MAYER, Holger WAGNER, Dieter WIEDENMAYER
  • HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS
    Publication number: 20240002363
    Abstract: Disclosed are heteroaromatic carboxamides of formula (I), wherein Y, R, and Ar are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are the use of the compounds of formula (i) for the treatment of diseases which can be influenced by the inhibition of plasma kallikrein.
    Type: Application
    Filed: August 25, 2023
    Publication date: January 4, 2024
    Inventors: Matthias ECKHARDT, Maude GIROUD, Elke LANGKOPF, Camilla MAYER, Holger WAGNER, Dieter WIEDENMAYER
  • Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors
    Patent number: 11851418
    Abstract: Disclosed are heteroaromatic carboxamides of formula (I), wherein R, R1, A1, A2, L1, and L2 are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are methods of using the compounds of formula (I) for treatment of diseases, which can be influenced by inhibition of plasma kallikrein.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: December 26, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Maude Giroud, Camilla Mayer, Holger Wagner, Dieter Wiedenmayer
  • Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists
    Publication number: 20230355638
    Abstract: The invention relates to cyclopentathiophene carboxamides of formula (I.0) wherein R1, R2, R3, R4, and n are as defined herein, and pharmaceutically acceptable salts thereof. The invention also relates to the use of the cyclopentathiophene carboxamides of formula (I.0) for the treatment of diseases which can be influenced by antagonizing the activity mediated by the platelet activating factor receptor.
    Type: Application
    Filed: July 14, 2023
    Publication date: November 9, 2023
    Inventors: Matthias ECKHARDT, Marina Kristina WILLWACHER, Juergen PRESTLE, Ferenc KONTES, Leo THOMAS, Christofer Siegfried TAUTERMANN, Dieter WIEDENMAYER
  • Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists
    Patent number: 11766443
    Abstract: The invention relates to cyclopentathiophene carboxamides of formula (I.0) wherein R1, R2, R3, R4, and n are as defined herein, and pharmaceutically acceptable salts thereof. The invention also relates to the use of the cyclopentathiophene carboxamides of formula (I.0) for the treatment of diseases which can be influenced by antagonizing the activity mediated by the platelet activating factor receptor.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: September 26, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Marina Kristina Willwacher, Juergen Prestle, Ferenc Kontes, Leo Thomas, Christofer Siegfried Tautermann, Dieter Wiedenmayer
  • Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors
    Patent number: 11760745
    Abstract: Disclosed are heteroaromatic carboxamides of formula (I), wherein Y, R, and Ar are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are the use of the compounds of formula (i) for the treatment of diseases which can be influenced by the inhibition of plasma kallikrein.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: September 19, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Maude Giroud, Elke Langkopf, Camilla Mayer, Holger Wagner, Dieter Wiedenmayer
  • Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists
    Publication number: 20230190763
    Abstract: Cyclopentathiophene carboxamides of formula (I), wherein R1, R2, R3, R4, and n are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of formula (I) can be used in methods for the treatment of diseases which can be influenced by antagonizing the activity mediated by the platelet activating factor receptor.
    Type: Application
    Filed: December 19, 2022
    Publication date: June 22, 2023
    Inventors: Matthias ECKHARDT, Ferenc KONTES, Christofer Siegfried TAUTERMANN, Dieter Wiedenmayer, Marina Kristina WILLWACHER
  • Synthesis of 1:1:1 co-crystal of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ß-d-glucopyranos-1-yl)-benzene, L-proline and water
    Patent number: 11629161
    Abstract: Intermediate compounds are described herein and which are used to manufacture a crystalline compound 1-cyano-2-(4-cyclopropyl-benzyl)-4-(?-D-glucopyranos-1-yl)-benzene L-proline monohydrate.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: April 18, 2023
    Inventors: Matthias Eckhardt, Monika Brink, Frank Himmelsbach, Stefan Sahli, Chutian Shu, Xiao-Jun Wang, Beat Theodor Weber, Bing-Shiou Yang
  • Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists
    Publication number: 20220160725
    Abstract: The invention relates to cyclopentathiophene carboxamides of formula (I.0) wherein R1, R2, R3, R4, and n are as defined herein, and pharmaceutically acceptable salts thereof. The invention also relates to the use of the cyclopentathiophene carboxamides of formula (I.0) for the treatment of diseases which can be influenced by antagonizing the activity mediated by the platelet activating factor receptor.
    Type: Application
    Filed: November 12, 2021
    Publication date: May 26, 2022
    Inventors: Matthias ECKHARDT, Marina Kristina WILLWACHER, Juergen PRESTLE, Ferenc KONTES, Leo THOMAS, Christofer Siegfried TAUTERMANN, Dieter WIEDENMAYER
  • SYNTHESIS OF 1:1:1 CO-CRYSTAL OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(ß-D-GLUCOPYRANOS-1-YL)-BENZENE, L-PROLINE AND WATER
    Publication number: 20220081461
    Abstract: Intermediate compounds are described herein and which are used to manufacture a crystalline compound 1-cyano-2-(4-cyclopropyl-benzyl)-4-(?-D-glucopyranos-1-yl)-benzene L-proline monohydrate.
    Type: Application
    Filed: November 30, 2021
    Publication date: March 17, 2022
    Inventors: Matthias ECKHARDT, Monika BRINK, Frank HIMMELSBACH, Stefan SAHLI, Chutian SHU, Xiao-Jun WANG, Beat Theodor WEBER, Bing-Shiou YANG
  • Synthesis of 1:1:1 co-crystal of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(?-D-glucopyranos-1-yl)-benzene, L-proline and water
    Patent number: 11225500
    Abstract: The invention relates to a process for the manufacture of the crystalline compound according to formula (I) comprising the steps (a) deacetylating the final intermediate (FI), (b) forming the crystalline compound according to formula (I) by reacting the deacetylated final intermediate of step (a) with L-proline and water and isolating the final reaction product; processes of manufacturing intermediates thereof; process intermediates and their uses in the processes according to the present invention.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: January 18, 2022
    Inventors: Matthias Eckhardt, Monika Brink, Frank Himmelsbach, Stefan Sahli, Chutian Shu, Xiao-Jun Wang, Beat Theodor Weber, Bing-Shiou Yang
  • HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS
    Publication number: 20210292301
    Abstract: Disclosed are heteroaromatic carboxamides of formula (I), wherein Y, R, and Ar are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are the use of the compounds of formula (i) for the treatment of diseases which can be influenced by the inhibition of plasma kallikrein.
    Type: Application
    Filed: February 11, 2021
    Publication date: September 23, 2021
    Inventors: Matthias ECKHARDT, Maude GIROUD, Elke LANGKOPF, Camilla MAYER, Holger WAGNER, Dieter WIEDENMAYER
  • HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS
    Publication number: 20210276976
    Abstract: Disclosed are heteroaromatic carboxamides of formula (I), wherein R, R1, A1, A2, L1, and L2 are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are methods of using the compounds of formula (I) for treatment of diseases, which can be influenced by inhibition of plasma kallikrein.
    Type: Application
    Filed: February 11, 2021
    Publication date: September 9, 2021
    Inventors: Matthias ECKHARDT, Maude GIROUD, Camilla MAYER, Holger WAGNER, Dieter WIEDENMAYER
  • SYNTHESIS OF 1:1:1 CO-CRYSTAL OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(ß-D-GLUCOPYRANOS-1-YL)-BENZENE, L-PROLINE AND WATER
    Publication number: 20210139520
    Abstract: The invention relates to a process for the manufacture of the crystalline compound according to formula (I) comprising the steps (a) deacetylating the final intermediate (FI), (b) forming the crystalline compound according to formula (I) by reacting the deacetylated final intermediate of step (a) with L-proline and water and isolating the final reaction product; processes of manufacturing intermediates thereof; process intermediates and their uses in the processes according to the present invention.
    Type: Application
    Filed: December 17, 2018
    Publication date: May 13, 2021
    Inventors: Matthias ECKHARDT, Monika BRINK, Frank HIMMELSBACH, Stefan SAHLI, Chutian SHU, Xiao-Jun WANG, Beat Theodor WEBER, Bing-Shiou YANG
  • Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
    Patent number: 10919859
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: February 16, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Holger Wagner, Stefan Peters
  • Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
    Patent number: 10913720
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: February 9, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Holger Wagner
  • Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
    Patent number: 10793530
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: October 6, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Holger Wagner
  • Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors
    Patent number: 10695334
    Abstract: Heteroaromatic carboxamides of formula (I), wherein Y, R, and X are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of formula (I) can be used in methods for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: June 30, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Andreas Gollner, Elke Langkopf, Holger Wagner, Dieter Wiedenmayer
  • Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
    Patent number: 10603317
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: March 31, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Holger Wagner